Current wearables can measure movement, but not muscle force.
The technology provides insight into motor control and human movement mechanics, and can be applied in orthopedics, rehabilitation, ergonomics, and sports.
The device is mounted on skin over a tendon, lightly tapping it 50 times per second. Each tap initiates a wave in the tendon, and two miniature accelerometers determine how quickly it travels. This assesses force via vibrational characteristics of the tendon change during loading. Tensile stress is then measured.
It has been used to measure forces on the Achilles tendon, patellar and hamstring tendons. Changes were observed when gait was modified, which can enable clinicians to optimize the treatment of musculoskeletal disease and injuries. It may also be useful to determine when a repaired tendon is healed.
Viz.ai‘s algorithms analyze brain scans and immediately transfer data to ensure rapid stroke treatment. The system connects to a hospital CT and sends alerts when a suspected LVO stroke has been identified. Radiological images are sent to a doctor’s phone. The company claims that the median time from picture to notification is less than 6 minutes, which can be life-saving, as they also claim that standard stroke workflow is now 66 minutes. Patient transfer to interventional centers is initiated through messaging and call capabilities connected with emergency and transportation services.
The signaling molecules, secreted by glia cells, affect mood, cognition and behavior.
The optical fiber sensor’s surface is treated with a capture protein that monitors the release of cytokine molecules in discrete and targeted parts of the brain. The goal is to understand cytokine secretion, neural circuits, and how they work together in brain health and disease.
5,000 types of metabolites can be analyzed for cancer biomarkers in urine. The team began a study three years ago, resulting in the identification of 30 metabolites that can be used to discriminate between healthy people and cancer patients. Further validation studies will begin in September at Nagoya University.
According to Sakairi: “For the comprehensive analysis of urine metabolites, we used a liquid chromatograph/mass spectrometer (LC/MS). Taking measurements with an LC/MS, and focusing on differences in the water-and fat-solubility of metabolites so as to optimize measurement conditions, we were able to detect over 1,300 metabolites in the urine samples. Using 30 biomarkers from among these, a look at their measured values for 15 cases each of breast cancer patients, colorectal cancer patients, and healthy subjects showed that we had made a breakthrough in being able to discriminate the difference between cancer and not cancer.”
Instead of defining the disease through symptoms such as memory or thinking problems, the researchers focus on biological changes, including brain plaques and tangles, determined by brain scans and spinal fluid tests.
The new approach can help researchers study patients with normal brain function who are likely to develop dementia, and help avoid misdiagnosis. Up to 30 per cent of behavior-based, Alzheimer’s diagnosed patients do not have the disease, with memory or thinking problems caused by something else.
MIT’s Arnav Kapur has created a device that senses and interprets neuromuscular signals created when we subvocalize. AlterEgo rests on the ear and extends across the jaw. A pad sticks beneath the lower lip, and another below the chin. It senses jaw and facial tissue bone-conduction, undetectable by humans.
Two bone-conduction headphones pick up inner ear vibrations, and four electrodes detect neuromuscular signals. Algorithms determine what a wearer is subvocalizing, and can report silently back. This enables communication with out speaking.
In studies, researchers interacted with a computer to solve problems; a participant asked a computer the time and got an accurate response; and another played a game of chess with a colleague.